

Supplementary Online Content

Berkowitz ST, Sternberg P Jr, Feng X, Chen Q, Patel S. Analysis of anti-vascular endothelial growth factor injection claims data in US Medicare Part B beneficiaries from 2012 to 2015. *JAMA Ophthalmol*. Published online June 20, 2019. doi:10.1001/jamaophthalmol.2019.1971

eTable 1. Trend in Anti-VEGF Injections Administered in Medicare Part B Population (2012-2015)

eTable 2. Geographic Disparities in Anti-VEGF Injections by State

This supplementary material has been provided by the authors to give readers additional information about their work.

eTable 1. Trend in Anti-VEGF Injections Administered in Medicare Part B Population (2012-2015)

	aflibercept				ranibizumab				bevacizumab			
	2012	2013	2014	2015	2012	2013	2014	2015	2012	2013	2014	2015
Total No. of Injections	NA	514 225	621 843	870 843	751 122	820 250	811 436	697 412	1 384 981	1 178 263	1 202 329	1 147 432
No. of Injections administered by top 100 injectors (% of national total)	NA	114 990 (22.4%)	122 709 (19.7%)	153 467 (17.6%)	239 321 (31.9%)	250 356 (30.5%)	237 418 (29.3%)	216 142 (31.0%)	235 095 (17.0%)	219 820 (18.7)	227 811 (19%)	225 083 (19.6%)

eTable 2. Geographic Disparities in Anti-VEGF Injections by State

Average No. of Injections per 1000 Medicare Part B Beneficiaries in 2015

all intravitreal injections		aflibercept		ranibizumab		bevacizumab	
Florida	102.1	Nebraska	48.6	Tennessee	48.4	South Dakota	51.9
Nebraska	99.0	Connecticut	41.2	Kansas	47.2	Indiana	51.2
Utah	97.6	Utah	38.6	Pennsylvania	38.9	Montana	49.5
South Dakota	94.9	Iowa	37.7	Utah	36.8	Idaho	49.3
Oregon	92.0	North Dakota	35.4	Iowa	34.9	South Carolina	49.1
New Hampshire	34.0	Alaska	9.1	District of Columbia	2.4	District of Columbia	16.2
District of Columbia	24.3	Vermont	7.7	New Hampshire	2.1	Alaska	12.6
Alaska	23.1	South Carolina	6.8	Alaska	1.0	Maine	10.7
Vermont	14.7	District of Columbia	3.2	Vermont	<1	Wyoming	8.3
Wyoming	10.6	Wyoming	2.7	Wyoming	<1	Vermont	6.1